Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis

Summary

This is a non-inferiority, Phase II, open-label, randomized, parallel trial to evaluate efficacy and safety of the new intervention (Dapaconazole cream 2%) versus the active control (Ketoconazole cream 2%) in patients with Tinea Pedis. Study schedule comprises enrollment, treatment and follow-up visits. Treatment period is 14 days.

Timeline

Start

2014-07

Primary completion

2014-12

Completion

2015-01

Drugs

Indications